Chief Medical Officer and Head of Research · Lexeo Therapeutics, Inc. (LXEO)

Eric Adler

A named executive officer of Lexeo Therapeutics in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$3,162,534

Salary $468,939Stock awards $456,875

FY2023: $3,042,824

3rd of 4 named executive officers at Lexeo Therapeutics by FY2024 total.

4 named officers on file for Lexeo Therapeutics, FY2024

Eric Adler’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Lexeo Therapeutics’s whole pay program stands against its peers

  • Lexeo Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LXEO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Eric Adler’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Eric Adler compensation by year

Lexeo Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Lexeo Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$296,500$468,939
Bonus$234,750$0
Stock awards—$456,875
Option awards$2,419,424$2,044,217
Non-equity incentive$80,750$171,000
Pension and deferred compensation$0$0
All other$11,400$21,503
Total$3,042,824$3,162,534

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Lexeo Therapeutics, Inc. DEF 14A filed April 28, 2025, accession 0000950170-25-059375, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Lexeo Therapeutics, Inc. filed document, accession 0000950170-25-059375. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2025.

$3.0M
$3.2M
FY23
FY24
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU26,875$176,838—
Option161,250—$17.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Lexeo Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

6 Form 4 lines since the FY2024 proxy (filed April 28, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-11-18Sale—615$9.2772,646
2025-10-17Sale—3,344$8.9473,299
2025-10-17Sale—38$9.5673,261
2025-10-15Grant or award—9,570$0.0076,643
2025-08-18Sale—608$4.6767,073
2025-05-16Sale—585$2.7767,681

The 6 most recent of 6 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Lexeo Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
R. Nolan TownsendChief Executive Officer and Director$4,375,248
Jose Manuel OteroChief Technical Officer$3,555,468
Eric Adler · this pageChief Medical Officer and Head of Research$3,162,534
Jenny RobertsonFormer Chief Legal Officer$2,485,110

The full Lexeo Therapeutics compensation record

free company brief

This page is one person within Lexeo Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Lexeo Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Eric Adler's compensation dossier · One-time report. No refunds.